Endometriosis

Endometriosis is the presence of functioning endometrial glands and stroma outside the uterine cavity. It is a chronic, oestrogen-dependent, inflammatory condition classically presenting in reproductive-age women with the triad of dysmenorrhoea, dyspareunia and infertility. For NEET PG it is one of the most reliably tested gynaecology chapters — pathogenesis theories, the chocolate cyst, CA-125, laparoscopy as gold standard, and drug-mechanism MCQs (GnRH agonists, dienogest) repeat almost every year.

Definition and key concepts

• Endometriosis = ectopic endometrial-like tissue (glands + stroma) outside the uterus, responsive to cyclical ovarian hormones.
• Adenomyosis = endometrial glands and stroma within the myometrium (endometriosis "interna"). A distinct entity, but commonly paired in MCQs (see differentials).
• Endometrioma = ovarian endometriotic cyst filled with altered, thick "chocolate-coloured" blood — the chocolate cyst.

High-yield: The ovary is the single most common site of endometriosis. Other frequent sites: uterosacral ligaments, pouch of Douglas (rectouterine pouch), broad ligament, rectovaginal septum, pelvic peritoneum. Most common extra-pelvic site is the bowel (rectosigmoid).

Classification / staging

The most-tested staging is the revised American Society for Reproductive Medicine (rASRM, formerly Revised-AFS) classification, based on a point score assigned at laparoscopy.

Stage	rASRM name	Point score
I	Minimal	1–5
II	Mild	6–15
III	Moderate	16–40
IV	Severe	> 40

High-yield: rASRM points are awarded for the size and depth of implants, presence/size of endometriomas, and density of adhesions (filmy vs dense; partial vs complete cul-de-sac obliteration). The score does NOT correlate with pain — a stage I patient may have severe pain and a stage IV patient may be asymptomatic.

Newer systems you may see in distractors: ENZIAN classification (for deep infiltrating/retroperitoneal disease) and the Endometriosis Fertility Index (EFI) which predicts spontaneous pregnancy after surgery.

Etiology and pathophysiology

No single theory explains all cases; examiners love the named theories.

Theory	Proposed by	Mechanism / explains
Retrograde menstruation (implantation)	Sampson	Menstrual blood with viable endometrium refluxes through tubes → implants on peritoneum. Most widely accepted. Explains pelvic/ovarian disease.
Coelomic metaplasia	Meyer / Iwanoff	Pluripotent peritoneal (coelomic) epithelium metaplasises into endometrium. Explains disease in prepubertal girls & rare male cases.
Lymphatic/vascular spread	Halban	Embolisation via lymphatics/veins. Explains distant sites (lung, brain, umbilicus).
Induction theory	—	Endogenous factor induces undifferentiated cells to form endometrium.
Stem cell / Müllerian remnant	—	Bone-marrow–derived or remnant Müllerian cells.

Pathophysiology in brief — an oestrogen-driven inflammatory loop:

Retrograde menstrual reflux → ectopic implants survive (impaired immune clearance) → local aromatase ↑ converts androgens to oestradiol → oestrogen drives growth + COX-2/prostaglandin release → inflammation, neoangiogenesis, fibrosis, adhesions → cyclical bleeding into closed spaces → pain & infertility.

Key molecular facts often tested:

• Ectopic lesions show ↑ aromatase and ↓ 17β-HSD type 2 → local hyperoestrogenism (basis of aromatase-inhibitor therapy).
• Progesterone resistance in eutopic + ectopic endometrium.
• Elevated prostaglandins (PGE2, PGF2α) and inflammatory cytokines (IL-1, IL-6, TNF-α) in peritoneal fluid → pain and impaired fertility.

High-yield: Endometriosis is an oestrogen-dependent disease. Hence it regresses in pregnancy and after menopause, and almost all medical therapies work by inducing a hypo-oestrogenic / pseudo-menopause or pseudo-pregnancy state.

Risk factors

Early menarche, late menopause, short cycles (<27 days), heavy/prolonged menses, nulliparity, Müllerian obstructive anomalies (e.g., imperforate hymen, obstructed horn), family history (7–10× risk in first-degree relative), low BMI. Protective: multiparity, prolonged lactation, combined OCPs, smoking (epidemiological, not recommended).

Clinical features

The classic "3 D's + I": Dysmenorrhoea, Dyspareunia, Dyschezia, Infertility.

• Secondary dysmenorrhoea — progressive, begins 1–2 days before menses, the most common symptom.
• Deep dyspareunia — especially with uterosacral/rectovaginal disease.
• Chronic pelvic pain, often non-cyclical with advanced disease.
• Infertility — present in 30–50%; mechanisms include distorted pelvic anatomy/adhesions, impaired ovum pick-up, poor oocyte/embryo quality, and a hostile inflammatory peritoneal environment.
• Cyclical symptoms at ectopic sites: cyclical haematuria/dysuria (bladder), dyschezia/rectal bleeding (bowel), cyclical haemoptysis (thoracic — catamenial pneumothorax/haemothorax, typically right-sided), scar endometrioma (cyclical pain & swelling in a Caesarean/episiotomy scar).
• Menstrual abnormalities: premenstrual spotting, menorrhagia (more with coexisting adenomyosis).

Examination signs (most-tested):

• Fixed, retroverted ("frozen") uterus.
• Tender nodularity of the uterosacral ligaments and posterior fornix — pathognomonic on bimanual/rectovaginal exam.
• Adnexal mass (endometrioma), often fixed and tender.

High-yield: A tender fixed retroverted uterus with nodular uterosacral ligaments in a young woman with dysmenorrhoea and infertility is the exam picture of endometriosis. Contrast with adenomyosis = symmetrically bulky, tender, "boggy" uterus.

Diagnosis and investigation of choice

Gold standard

High-yield: Laparoscopy with visualisation of lesions (± histological confirmation) is the GOLD STANDARD for diagnosing endometriosis. It allows simultaneous staging (rASRM) and treatment.

Laparoscopic appearances:

• Classic "powder-burn" / "gunshot" black-bluish lesions and puckered black implants.
• Red flame-shaped lesions (active, early), white fibrotic lesions (old/healed), and "matchstick" vascular lesions.
• Endometrioma: ovarian cyst with thick chocolate-coloured fluid; adhesions to ovarian fossa.
• Histology: endometrial glands + stroma ± haemosiderin-laden macrophages.

Imaging

• Transvaginal ultrasound (TVS) — first-line/initial imaging and investigation of choice for an endometrioma. Classic features:
  • Unilocular cyst with homogeneous low-level "ground-glass" echoes.
  • Thick walls, no internal vascularity on Doppler, may be bilateral.
• MRI — best for deep infiltrating endometriosis (DIE), rectovaginal septum and bowel/bladder involvement and surgical mapping. Endometrioma shows T1 hyperintense, T2 "shading" sign.

Serum marker

• CA-125 — may be raised (esp. moderate–severe disease), but non-specific and NOT diagnostic; used mainly to monitor recurrence/response, not for screening. Normal CA-125 does not exclude disease.

High-yield: TVS = best for ovarian endometrioma; MRI = best for deep infiltrating disease; CA-125 = follow-up, not a diagnostic/screening test; laparoscopy = definitive gold standard.

Diagnostic flow:

1. Suspicious history + exam (tender USL nodularity, fixed uterus) →
2. TVS (detects endometrioma/DIE; normal scan does not rule out peritoneal disease) →
3. MRI if deep/bowel/bladder disease suspected →
4. Diagnostic laparoscopy for confirmation, staging and concurrent treatment.

Management

Tailored to symptom (pain vs infertility), severity, age, and fertility desire. Two arms: medical (suppress ectopic tissue) and surgical (excise/ablate, restore anatomy).

A. Pain — medical therapy

All medical drugs are suppressive, not curative, and contraceptive (so unsuitable when fertility is desired).

Drug class	Example	Mechanism	Key adverse effects
NSAIDs	Mefenamic acid, ibuprofen	↓ Prostaglandin (first-line for pain)	Gastritis
Combined OCPs	EE + progestin (often continuous)	Decidualisation + atrophy of implants, ↓ menstruation	VTE risk
Progestins	Dienogest, MPA, NETA	Decidualisation → atrophy; anti-inflammatory; dienogest is a first-line oral progestin	Breakthrough bleeding, weight gain
LNG-IUS (Mirena)	—	Local progestin → endometrial atrophy; good for pain + adenomyosis	Irregular spotting
GnRH agonists	Leuprolide, goserelin, nafarelin	Pituitary down-regulation → hypo-oestrogenic pseudo-menopause	Hot flushes, bone loss — limit ≤6 months or add add-back
GnRH antagonists	Elagolix, relugolix	Immediate ↓ GnRH receptor → dose-dependent oestrogen suppression (oral)	Hot flushes, bone loss
Aromatase inhibitors	Letrozole, anastrozole	Block local + ovarian oestrogen synthesis (refractory disease, with add-back)	Bone loss, ovarian cysts
Danazol (historical)	—	Androgenic; pseudo-menopause	Hirsutism, acne, voice change, weight gain — now rarely used

High-yield (mechanism MCQs):

• GnRH agonist → initial flare then down-regulation/desensitisation of pituitary GnRH receptors → ↓ FSH/LH → hypo-oestrogenic state. Use ≤6 months; add "add-back" therapy (low-dose oestrogen + progestin) to protect bone if longer.
• Dienogest — a selective progestin, first-line for endometriosis-associated pain, causes decidualisation and atrophy of lesions with an anti-inflammatory effect; well tolerated long-term.
• Danazol acts by creating a high-androgen, low-oestrogen environment (inhibits the mid-cycle LH surge and steroidogenic enzymes).

B. Surgical therapy

• Conservative (fertility-preserving) laparoscopy — excision/ablation of implants, cystectomy for endometrioma (excision of cyst wall is superior to drainage/ablation — lower recurrence, better fertility), adhesiolysis, restoration of anatomy. Laparoscopy is preferred over laparotomy.
• LUNA (laparoscopic uterosacral nerve ablation) / presacral neurectomy — for midline pain (limited evidence; presacral neurectomy helps central dysmenorrhoea).
• Definitive surgery — total hysterectomy + bilateral salpingo-oophorectomy (TAH-BSO) with excision of all lesions, for women with completed family and intractable disease. Oophorectomy removes the oestrogen drive.

High-yield: For an endometrioma, laparoscopic cystectomy (stripping the cyst wall) has lower recurrence and better pain relief than fenestration/coagulation — but caution: excessive stripping can reduce ovarian reserve (↓ AMH).

C. Infertility-associated endometriosis

Medical suppression does NOT improve fertility (it only delays conception by suppressing ovulation). Options:

• Stage I–II (minimal/mild): laparoscopic ablation/excision of lesions modestly improves spontaneous conception; or proceed to ovulation induction + IUI.
• Stage III–IV (moderate/severe) or failed conservative measures, or endometrioma with declining reserve: IVF/ART is the mainstay.
• Endometriosis Fertility Index (EFI) helps counsel on chance of spontaneous pregnancy post-surgery.

Pain management decision flow:

Confirmed/suspected endometriosis with pain → NSAIDs + combined OCP/progestin (dienogest) → if inadequate, GnRH agonist/antagonist (≤6 mo + add-back) → if refractory or large endometrioma, laparoscopic excision → completed family + intractable → TAH-BSO.

Complications

• Infertility / subfertility (most clinically important).
• Endometrioma rupture → acute abdomen / chemical peritonitis.
• Dense adhesions → frozen pelvis, chronic pain, bowel/ureteric obstruction.
• Ureteric obstruction → silent hydronephrosis with DIE near the ureter (a feared, often asymptomatic complication).
• Bowel obstruction / cyclical rectal bleeding with bowel involvement.
• Catamenial pneumothorax / haemoptysis (thoracic endometriosis, usually right side).
• Recurrence after conservative surgery is common (≈ 20–40% over 5 years).
• Malignant transformation — rare (<1%); the classic associated cancers are endometrioid and clear-cell carcinoma of the ovary arising in an endometrioma.

High-yield: An endometrioma that suddenly enlarges, develops solid/vascular areas, or rising CA-125 in a postmenopausal patient → suspect clear-cell or endometrioid ovarian carcinoma.

Key differentials

Feature	Endometriosis	Adenomyosis	PID / chronic salpingitis
Typical age	25–35, often nulliparous	35–45, multiparous	Any, sexually active
Uterus	Fixed, retroverted, USL nodules	Symmetrically bulky, "boggy", tender	Tender, may be mobile early
Pain	Secondary dysmenorrhoea + dyspareunia	Dysmenorrhoea + menorrhagia	Pain + fever, discharge
Best imaging	TVS (endometrioma), MRI (DIE)	MRI: junctional zone >12 mm; TVS heterogeneity	USG (tubo-ovarian mass), clinical
Marker	CA-125 (follow-up)	—	↑ WBC, ↑ CRP, positive cultures
Diagnosis	Laparoscopy (gold standard)	Histology post-hysterectomy / MRI	Clinical + microbiology
Fertility	Reduced	Usually preserved	May cause tubal infertility

Other differentials: haemorrhagic ovarian cyst, ectopic pregnancy, ovarian neoplasm, irritable bowel syndrome, interstitial cystitis, primary dysmenorrhoea.

Recently asked / exam angle

• Most common site of endometriosis → ovary; most common extrapelvic site → bowel (rectosigmoid).
• Gold standard diagnosis → laparoscopy; do not pick CA-125 or USG.
• Chocolate cyst = ovarian endometrioma; TVS shows ground-glass / homogeneous low-level echoes; MRI shows T2 shading.
• Sampson's theory = retrograde menstruation (most accepted); Meyer/Iwanoff = coelomic metaplasia; Halban = vascular/lymphatic spread — match the eponym.
• GnRH agonist mechanism = pituitary down-regulation → hypo-oestrogenic state; limit to 6 months + add-back.
• Dienogest = first-line progestin for endometriosis pain.
• Danazol adverse effects = androgenic (hirsutism, acne, voice change) — classic single-best-answer.
• rASRM staging does not correlate with pain; cul-de-sac obliteration and adhesions score points.
• For endometrioma → cystectomy (wall stripping) preferred over drainage; but watch ovarian reserve.
• Catamenial pneumothorax is the buzzword for thoracic endometriosis (usually right-sided).
• Endometriosis-related ovarian cancers → clear-cell and endometrioid subtypes.
• Medical therapy does not improve fertility; severe disease/infertility → IVF.

Rapid revision

1. Endometriosis = functioning endometrial glands + stroma outside the uterus; oestrogen-dependent, inflammatory.
2. Ovary = commonest site; rectosigmoid = commonest extrapelvic site.
3. Triad: dysmenorrhoea + dyspareunia + infertility; sign = fixed retroverted uterus + tender USL nodularity.
4. Sampson = retrograde menstruation (most accepted theory).
5. Laparoscopy = gold standard diagnosis; classic powder-burn lesions + chocolate cyst.
6. Chocolate cyst = endometrioma; TVS = best initial imaging (ground-glass echoes); MRI (T2 shading) = deep disease.
7. CA-125 is non-specific — used for follow-up, not diagnosis.
8. rASRM staging (minimal→severe) does not correlate with pain severity.
9. First-line pain therapy: NSAIDs + combined OCP/dienogest; GnRH agonist ≤6 months + add-back.
10. Danazol → androgenic side effects (hirsutism, acne, deep voice) — now rarely used.
11. Endometrioma → laparoscopic cystectomy (better than drainage), but protect ovarian reserve (AMH).
12. Severe disease + infertility → IVF; completed family + intractable → TAH-BSO; malignant risk → clear-cell/endometrioid ovarian cancer.